
Specialty medical devices provider Teleflex, Inc. (TFX) substantially raised its full-year 2025 guidance, now projecting adjusted earnings from continuing operations of $13.90-$14.30 per share and revenue growth of 9-10%. This revised outlook significantly exceeds both the company's prior expectations and current analyst consensus of $13.39 adjusted EPS and 2.94% revenue growth, signaling strong business momentum. The company also declared a $0.34 per share quarterly dividend.
Teleflex, Inc. (TFX) has issued a significant upward revision to its full-year 2025 guidance, signaling a material acceleration in business performance. The company now projects revenue growth of 9% to 10%, a dramatic increase from the prior forecast of 1.28% to 2.28% and substantially above the analyst consensus of 2.94%. This top-line strength is further supported by a new constant currency adjusted revenue growth forecast of 7.70% to 8.70%, indicating the improvement is driven by fundamental business operations rather than currency fluctuations. Concurrently, the adjusted earnings per share (EPS) guidance was raised to a range of $13.90 to $14.30, with the new midpoint comfortably exceeding both the previous guidance midpoint ($13.40) and the current Wall Street consensus of $13.39. This powerful combination of a beat-and-raise, particularly on the revenue front, suggests that prior expectations were overly conservative and that the company is experiencing strong underlying demand for its medical devices. The declaration of a $0.34 quarterly dividend reinforces the board's confidence in the company's financial stability and cash flow generation.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.80
Ticker Sentiment